Clinical trial
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland…
NCT00126607 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00126607 |
|---|---|
| Title | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer |
| Official title | Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer |
| Intervention type | Biological, Other |
| Interventions | trastuzumab, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2007 |
| First posted | Aug 4, 2005 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: